Publikationen

Artikel & Studien

Ausgewählte Veröffentlichungen in internationalen Fachjournalen.

21 von 21 Einträgen

Gesellschaftlicher Wert pharmazeutischer Innovationen für Österreich.
E. Walter
Mai 2025
PDF: Gesellschaftlicher Wert pharmazeutischer Innovationen für Österreich.
Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.
E. Walter, F. Torelli, T. Barbui
Annals of Hematology. Jan 2025
Zum Artikel : Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.
Cost-effectiveness of the Floodlight® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis.
E. Walter, M. Traunfellner, F. Meyer, C. Enzinger, M. Guger, C. Bsteh, P. Altmann, H. Hegen, C. Goger, V. Mikl
Digital Health. Jan 2025
Zum Artikel : Cost-effectiveness of the Floodlight® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis.
Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.
E. Walter, C. Dawoud, E. Hütterer, A. Stift, F. Harpain
The American journal of clinical nutrition. 2024
%20amounts%20to%20123%2C945%20%E2%82%AC)
Zum Artikel : Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.
A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: an original research.
G. Eichhober, M. Voit, F. Meyer, E. Walter
Health Sci Rep. 2024
Zum Artikel : A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: an original research.
The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria.
E. Walter, M. Traunfellner, M. Gleitsmann, M. Zalesak, C. Helmenstein
J Med Econ. 2023
Zum Artikel : The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria.
Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland.
E. Walter, M. Arrigo, S. Allerstorfer, P. Marty, M. Hülsmann
J Med Econ. 2023
Zum Artikel : Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland.
Exploring the Economic and Social Dimension of COVID-19 Vaccination Using a Budget Impact Analysis.
M. Traunfellner, F. Meyer, E. Walter
Value & Outcomes Spotlight. 2022
(Seite 18-21)
Zum Artikel : Exploring the Economic and Social Dimension of COVID-19 Vaccination Using a Budget Impact Analysis.
Impact of metabolic surgery on long-term health outcome: a cost-effectiveness approach.
E. Walter, F. B. Langer, P. Beckerhinn, F. Hoffer, G. Prager
Surg Obes Relat Dis. 2022
Zum Artikel : Impact of metabolic surgery on long-term health outcome: a cost-effectiveness approach.
Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
E. Walter, M. Voit, G. Eichhober
Expert Rev Pharmacoecon Outcomes Res. 2021
Zum Artikel : Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria.
E. Walter, S.C. Hausberger, E. Groß, U. Siebert
J Med Econ. 2020
Zum Artikel : Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria.
Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.
E. Walter, G. Eichhober, M. Voit, C. Baumgartner, A. Celedin, C. Holzhauser, B. Mraz, C. Ornauer, J. Pleiner-Duxneuner, B. Ponner, I. Presch, G. Pum, H. Tieben, G. Weingartmann, D. Baltic, W. Bonitz, S.T. Kaehler.
J Med Econ. 2020
Zum Artikel : Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.
Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System.
E. Walter, M. Heringlake
J Cardiothorac Vasc Anesth. 2019 Nov 9.
Zum Artikel : Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System.
Approaches to Capturing Value in Oncology.
E. Walter
In: E. Walter (eds) Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research, vol 213. Springer, Cham
Zum Artikel : Approaches to Capturing Value in Oncology.
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
E. Walter, T. Berger, B. Bajer-Kornek, F. Deisenhammer
J Med Econ. 2019 Mar; 22(3): 226-237.
Zum Artikel : Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.
E. Walter, H. Dellago, J. Grillari, H. P. Dimai
Hackl M. Bone. Mar 2018; 108:44-54
Zum Artikel : Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.
Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.
A. R. Prusa, D.C. Kasper, L. Sawers, E. Walter, M. Hayde, E. Stillwagon
PLoS Negl Trop Dis., Jul 2017
Zum Artikel : Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany
E. Walter, P. Odin
J Med Econ. 2015 Feb; 18(2):155-65.
Zum Artikel : Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany
Socio-economic aspects of the testing for antibodies in MS-Patients under Interferon Therapy in Austria: A cost of Illness Study
E. Walter, F. Deisenhammer
Multiple Sclerosis and Related Disorders. 2014, Volume 3, Issue 6, Pages 670-677.
Zum Artikel : Socio-economic aspects of the testing for antibodies in MS-Patients under Interferon Therapy in Austria: A cost of Illness Study
Kosteneffektivität der primärprofilatischen Gabe von Pegfilgrastim vs. Filgrastim bei Brustkrebspatienten in Österreich
E. Walter
Recht der Medizin Beilage Gesundheit und Ökonomie, Dezember 2013
Cost Efectividad del Tratamiento de la Anemia inducida por quimioteerapia con agentes estimuladores dela Eritropoyesis
C. A. Rodríguez, A. Alegre, J. Cassinello, L. Guiérrez, C. Crespo, A. Villacampa, E. Walter
PharmaEconomics Spanish Resarch Articles, August 2013
Zum Artikel : Cost Efectividad del Tratamiento de la Anemia inducida por quimioteerapia con agentes estimuladores dela Eritropoyesis

Ältere Veröffentlichungen finden Sie im Artikel-Archiv.

Artikel & Studien

Gesellschaftlicher Wert pharmazeutischer Innovationen für Österreich.

Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system.

Cost-effectiveness of the Floodlight® MS app in Austria. Unlocking the mystery of costs and outcomes of a digital health application for patients with multiple sclerosis.

Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.

A budget impact analysis of a powered hybrid mattress to prevent pressure ulcers in the Austrian inpatient setting: an original research.

The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria.

Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type 2 diabetes in Austria and Switzerland.

Exploring the Economic and Social Dimension of COVID-19 Vaccination Using a Budget Impact Analysis.

Impact of metabolic surgery on long-term health outcome: a cost-effectiveness approach.

Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.

Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria.

Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria.

Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System.

Approaches to Capturing Value in Oncology.

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.

Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population.

Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.

Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany

Socio-economic aspects of the testing for antibodies in MS-Patients under Interferon Therapy in Austria: A cost of Illness Study

Kosteneffektivität der primärprofilatischen Gabe von Pegfilgrastim vs. Filgrastim bei Brustkrebspatienten in Österreich

Cost Efectividad del Tratamiento de la Anemia inducida por quimioteerapia con agentes estimuladores dela Eritropoyesis